Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 2, 2025, covers Trevi Therapeutics, Inc., a Delaware corporation developing Haduvio (oral nalbuphine ER). The filing announces positive topline results from the Phase 2b CORAL clinical trial evaluating Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial outcomes and future development plans.
Material Changes and Clinical Results
The primary endpoint of the Phase 2b CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all Haduvio dose groups at Week 6 compared to placebo.
- Primary Endpoint Results (Week 6):
- 108 mg BID: -60.2% reduction (p<0.0001)
- 54 mg BID: -53.4% reduction (p<0.0001)
- 27 mg BID: -47.9% reduction (p<0.01)
- Placebo: -16.9% reduction
- Secondary Endpoints: Statistically significant improvements were observed in cough severity (CS-NRS) and the E-RS IPF Cough Subscale for the 108 mg and 54 mg dose groups.
- Safety Profile: Discontinuation rates due to adverse events were similar between Haduvio groups (5.6%) and placebo (5.0%). Serious adverse events were reported in 1.6% of Haduvio patients versus 10.0% of placebo patients. Common adverse events included nausea, vomiting, constipation, dizziness, headache, fatigue, somnolence, and dry mouth.
Guidance, Outlook, and Risks
Management outlined the following strategic milestones and expectations:
- Regulatory Engagement: The Company expects to request an end of Phase 2 meeting with the FDA in the second half of 2025 to align on the Phase 3 program for Haduvio in IPF.
- Future Trials:
- Initiation of a trial for chronic cough in non-IPF interstitial lung disease in the second half of 2025, with topline results expected in the second half of 2026.
- Initiation of a Phase 2b trial for refractory chronic cough in the first half of 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include uncertainties regarding the success, cost, and timing of clinical trials; the possibility that positive Phase 2 data may not predict Phase 3 results; regulatory authority views on the data; and the Company's ability to fund future operations and clinical trials.
Investor Verification Checklist
- Verify the specific statistical significance (p-values) and confidence intervals for the secondary endpoints in the full clinical study report.
- Confirm the Company's current cash runway and funding status to support the planned Phase 3 program and new trials, as no financial data is provided in this 8-K.
- Monitor the outcome of the anticipated end of Phase 2 meeting with the FDA in late 2025.
- Review the detailed safety data regarding the specific adverse events and their severity compared to historical data for nalbuphine.